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AbstrACt
Objective To evaluate the impact of treatment with new 
direct-acting antivirals (DAAs) on the prevalent hepatitis C 
virus (HCV) population in England.
Design A repeated cross-sectional analysis.
setting Four secondary care hospitals in England.
Participants Patients who, in 2015 and/or 2016, had 
chronic HCV infection and were alive were eligible, 
regardless of the type of HCV intervention received.
Outcome measures Data including intravenous drug 
use (IVDU) status, HCV genotype, cirrhosis status, HCV 
treatment history, vital status and treatment outcomes 
were collected at two time points in 2015 and 2016 using 
electronic case report forms.
results There were 1605 and 1355 patients with active 
chronic HCV in 2015 and 2016, respectively. Between 
2015 and 2016, the proportion of patients with current 
IVDU increased (10.3% vs 14.5%, respectively), while that 
of patients with cirrhosis (28.2% vs 22.4%) and treatment-
experienced patients (31.2% vs 27.1%) decreased. Among 
patients whose treatment outcome was known by 2016, 
high cure rates were observed, with an overall sustained 
virological response rate of 93.2%. From 2015 to 2016, 
there was a progressive increase in the proportion of 
treated patients who were non-cirrhotic, with current IVDU 
and non-liver transplant recipients.
Conclusions The characteristics of patients with HCV 
remaining in contact with specialised care evolved with a 
changing landscape of treatment and related health policy. 
With increasing access to DAAs in UK, high cure rates 
were achieved in the study cohort.
IntrODuCtIOn
Worldwide, infection with the bloodborne 
hepatitis C virus (HCV) is estimated to cause 
399 000 deaths every year.1 Although some of 
those infected with HCV clear the virus spon-
taneously, the remaining 60%–80% develop 
chronic hepatitis C.1 Patients with chronic 
hepatitis are at high risk of developing severe 
liver disease, including cirrhosis (15%–30% 
risk over 20 years1) and hepatocellular carci-
noma (1%–3% risk over 30 years2), which 
directly cause the majority of HCV-related 
deaths.1 Consequently, chronic HCV is consid-
ered a major public health threat,3 4 affecting 
214 0003 people in the UK and 160 000 
in England alone.4 Intravenous drug use 
(IVDU) is a significant contributor to HCV 
spread; in 2016, more than half of the people 
in England who injected psychoactive drugs 
were also infected with HCV.4 
The recent availability of direct-acting 
antivirals (DAAs) offers many HCV-infected 
patients the chance of a cure, with sustained 
virological response (SVR) rates commonly 
exceeding 90% in clinical trials5–7 and real-
world studies alike.8–12 While treatment 
recommendations are genotype (GT)-spe-
cific,13 new DAAs are generally considered to 
be safe and highly effective. In the UK, access 
strengths and limitations of this study
 ► The study describes how the characteristics of pa-
tients with hepatitis C virus (HCV) remaining in con-
tact with specialised care evolved with the changing 
landscape of treatment since the introduction of 
direct-acting antivirals and provides important re-
al-world data on the outcomes of antiviral treatment 
among a diverse patient cohort.
 ► Patient information was collected from four hospitals 
in England, and so the generalisability of our findings 
should be considered against the study setting and 
the range of data collected.
 ► The collection of patient information from four spe-
cialist hospitals gives valuable insight into the treat-
ment of HCV in secondary care.
 ► The developments in the treatment of HCV in the 
last 2 years may mean that the characteristics of 
patients currently receiving treatment have changed 
from those described in our study.
 ► The retrospective nature of data collection could 
subject it to issues related to data access, complete-
ness and accuracy.
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to DAAs has been initially prioritised for patients with 
the most severe liver disease. This reflected the relatively 
high acquisition costs of DAAs compared with historical 
standards of care, and the significant patient and health 
system savings expected from the avoidance of HCV-re-
lated complications and mortality.14 Understanding the 
nature of the remaining untreated or uncured HCV 
population, and the outcomes of patients treated with 
DAAs, is important to both clinicians and policy makers 
in guiding ongoing and future efforts to eradicate HCV 
infection.
This study aimed to demonstrate the impact of new 
DAAs on the prevalent population with known HCV 
infection in England following their launch, facilitating 
the understanding of both the remaining burden of 
known HCV infection and the future needs of HCV-in-
fected populations, including potential barriers to eradi-
cating HCV. Specifically, the study aimed to address four 
objectives: (1) evaluate the change in size and character-
istics of the population with active chronic HCV infection 
between September 2015 and September 2016 at four 
hospitals in England; (2) describe the antiviral treatment 
patterns and outcomes in adult patients with chronic 
HCV infection over a 1-year period from September 
2015; (3) characterise patients who were lost to follow-up 
(LTFU), to understand how they may be re-engaged with 
care and antiviral treatment; and (4) provide insights 
into the likely emerging and future needs of patients with 
HCV in the DAA era, by describing the characteristics of 
patients who were newly referred during the 12-month 
observation period (ie, between 15 September 2015 and 
15 September 2016) and comparing them with those of 
patients already in contact with care at study onset.
MethODs
Patient and public involvement
The study was retrospective and observational in design, 
and as such patients and the public were not involved in 
the design and implementation of the study.
study settings
Within England, prior to June 2015, DAA usage was 
initially provided via early access schemes. Since June 
2015, DAAs have been available, but the roll-out has been 
prioritised for people with advanced HCV-related liver 
disease, specifically patients with compensated cirrhosis 
extending to all GT1 patients and GT3 patients who were 
contraindicated to interferon (IFN)-based regimens.15 
Although patients with cirrhosis were still prioritised, 
there was a further roll-out to non-cirrhotic patients from 
April 2016.
Within England, recent estimates put the undiagnosed 
HCV population at approximately 50%.16 Testing for 
HCV is typically performed on a targeted basis within 
primary care, be it within general practice of specialised 
sexual health clinics based on high-risk groups, including 
but not limited to IVDU/other drug use, existing blood/
organ transplants (prior to 1992), originating from high-
risk countries, in regular sexual contact with patients diag-
nosed with HCV and babies born to mothers diagnosed 
with HCV.17 Diagnoses are performed in primary care, 
and those positive will be referred to an HCV specialist 
within secondary care where treatment and monitoring 
take place.
study design
This repeated open cohort study was based on historical 
data collection at two different time points: 15 September 
2015 and 15 September 2016 (hereby referred to as 2015 
and 2016, respectively), which served, respectively, as 
index dates for the 2015 and 2016 cohorts of patients with 
active HCV infection.
Four hospitals in England participated: Birmingham 
(Queen Elizabeth Hospital, Birmingham), Liverpool 
(Royal Liverpool University Hospital), Hull (Hull and 
East Yorkshire Hospitals NHS Trust) and Portsmouth 
(Queen Alexandra Hospital, Portsmouth). These hospi-
tals were chosen to be broadly representative (geograph-
ical and sociodemographics) of patients in specialist care 
in England.
study population
Study populations were defined with the four study objec-
tives in mind. To evaluate the change in size and character-
istics of the population with active chronic HCV infection 
between 2015 and 2016, two patient cohorts were created: 
2015 active HCV cohort and 2016 active HCV cohort. The 
2015 active HCV cohort included all alive adult patients 
with chronic HCV infection prior to 15 September 2015, 
defined as patients with viraemia at the most recent atten-
dance at a specialist HCV appointment for any reason, 
patients who were on antiviral therapy, or patients who 
had recently completed antiviral therapy but were yet 
to complete the 12-week post-treatment assessment of 
response. The 2016 active HCV cohort included patients 
part of the 2015 active HCV cohort who were alive but not 
cured as of 15 September 2016, as well as newly referred 
patients post 15 September 2015 meeting the same inclu-
sion criteria. Patients with a known diagnosis of HCV who 
had attended the study centres at some stage but who had 
not been seen within the 24-month period prior to the 
index date were excluded. Patients’ demographic and 
clinical characteristics, and previous and current HCV 
treatment received at time of their last visit prior to the 
index date, were collected.
To describe antiviral treatment patterns and outcomes 
over 1 year from the index date in adult patients with 
chronic HCV infection, clinical characteristics, treat-
ments received and vital status at the time of the last visit 
prior to the 2016 index date were collected for all patients 
included in the 2015 active HCV cohort, except for those 
without a visit in the preceding 24 months.
Patients who were included in the 2015 active HCV 
cohort but were not seen in the study centres within 24 
months prior to the 2016 active HCV cohort index date 
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were considered LTFU. Characterising this cohort was of 
interest, as it could help design strategies aiming to re-en-
gage them with care and facilitate uptake of antiviral treat-
ment among this potentially challenging patient group.
Finally, to predict the changing needs of patients with 
HCV enrolling for treatment in the DAA era, we char-
acterised (as of 2016) eligible patients who were newly 
referred to the study centres within the 1-year observation 
period and compared them with the prevalent 2015 active 
HCV cohort, which included patients who had been in 
contact with secondary care services over a period prior 
to DAA introduction.
Data collection
An electronic case report form (eCRF), designed to 
capture demographic and clinical data collected from 
existing databases or historical review of medical records, 
was used as the primary instrument for data collection by 
hospital staff members, which was entirely retrospective 
and performed poststudy.
Data collected within the eCRF at each time point 
included the following: IVDU status, HCV genotype; 
most recent viral load; liver fibrosis status (non-cirrhotic 
(F0–F2, F3, no F-score), cirrhotic (compensated, decom-
pensated, without precision)); HIV coinfection; liver 
transplantation status; previous and current HCV treat-
ment received (regimens received and start date/end 
date); and vital status (alive, death related to HCV infec-
tion, death for other reason). Furthermore, outcomes 
related to treatment received during the observation 
period were recorded, including no response, break-
through, interruption due to adverse drug reaction, 
relapse, SVR achieved and unknown.
statistical analyses
Patient demographic and clinical characteristics were 
described using summary statistics. Continuous variables 
were reported as mean with SD, median, minimum, 
maximum, and first and third quartiles. Categorical 
variables were reported as counts, proportions and its 
95% CI. The number and percentage of patients with 
missing data for each variable were described. Due to the 
retrospective nature of the trial, missing data were catego-
rised as missing for all continuous variables. The changes 
in the size and the characteristics of the population with 
active infection between 2015 and 2016 were described by 
calculating the absolute difference in patients counts and 
variables distribution (%) between 2015 and 2016.
results
The patient populations are summarised in figure 1. The 
2015 active HCV cohort included 1605 patients with active 
HCV infection at index date. Of those, 22.9% achieved 
SVR prior to 2016 (368 patients, including 3 patients 
who died after achieving SVR) and 1.6% died without 
achieving SVR (26 patients). Among the 2015 active HCV 
cohort, 154 (9.6%) patients with no visits within the last 
24 months prior to 2016 were considered LTFU and were 
excluded from the 2016 active HCV cohort.
An additional 337 patients with HCV were newly 
referred to the participating centres during the 12-month 
observation period, of whom 88.4% had an active HCV 
infection at the time of the last visit before 2016, 10.1% 
achieved SVR after referral and before 2016, and 1.5% 
died without SVR. Thus, the 2016 active HCV cohort 
included 1355 patients with active HCV infection at index 
date.
Change in the characteristics of the active hCV population 
between 2015 and 2016
Overall, the active HCV population reduced by 250 
patients (−15.6%) between 2015 and 2016 (table 1). 
The largest proportion of patients from both 2015 and 
2016 active HCV cohorts were enrolled at Birmingham 
(701 and 459 patients, respectively). The changes in the 
size of the active HCV population varied widely across 
Figure 1 Study patient populations. HCV, hepatitis C virus; HepC, hepatitis C; SVR, sustained virological response. 
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Table 1 Change in the characteristics of the active HCV population between 2015 and 2016
2015 active HCV cohort 2016 active HCV cohort
Changes in active HCV 
cohort between 2015 
and 2016
n % (95% CI) n % (95% CI)
Difference 
(n)
Difference 
(%)
Overall population 1605 1355 −250
Centre
  Birmingham 701 43.7 (41.25 to 46.1) 459 33.9 (31.4 to 36.4) −242 −9.8
  Hull 307 19.1 (17.20 to 21.1) 401 29.6 (27.2 to 32.0) 94 10.5
  Liverpool 485 30.2 (27.97 to 32.5) 410 30.3 (27.8 to 32.7) −75 0.0
  Portsmouth 112 7.0 (5.73 to 8.2) 85 6.3 (5.0 to 7.6) −27 −0.7
Age at index date 
(years)
  Mean (SD) 48.9 (11.4) 47.6 (11.1) −1.4 years
  Median 49 47 −2.0 years
  Q1–Q3 41–56 40–55
  Minimum–maximum 18–83 19–84
Male 1197 74.6 (72.4 to 76.7) 997 73.6 (71.2 to 75.9) −200 −1.0
IVDU
  Current IVDU 165 10.3 (8.8 to 11.8) 196 14.5 (12.6 to 16.3) 31 4.2
  Prior IVDU 705 43.9 (41.5 to 46.4) 638 47.1 (44.4 to 49.7) −67 3.2
  Never IVDU 306 19.1 (17.1 to 21.0) 238 17.6 (15.5 to 19.6) −68 −1.5
  Not recorded 429 26.7 (24.6 to 28.9) 283 20.9 (18.7 to 23.1) −146 −5.8
Genotype
  GT1 704 43.9 (41.4 to 46.3) 582 43.0 (40.3 to 45.6) −122 −0.9
  GT2 72 4.5 (3.5 to 5.5) 60 4.4 (3.3 to 5.5) −12 −0.1
  GT3 660 41.1 (38.7 to 43.5) 556 41.0 (38.4 to 43.7) −104 −0.1
  Other 106 6.6 (5.4 to 7.8) 91 6.7 (5.4 to 8.0) −15 0.1
  Missing information 63 3.9 (3.0 to 4.9) 66 4.9 (3.7 to 6.0) 3 0.9
Liver disease status
Any cirrhosis 452 28.2 (25.8 to 30.6) 304 22.4 (20.2 to 24.7) −148 −5.7
  Decompensated 
cirrhosis
67 4.2 (3.1 to 5.2) 45 3.3 (2.4 to 4.3) −22 −0.9
  Compensated
  cirrhosis
378 23.6 (21.3 to 25.8) 256 18.9 (16.8 to 21.0) −122 −4.7
  Cirrhosis (no 
precision)
7 0.4 (0.1 to 0.8) 3 0.2 (0.0 to 0.5) −4 −0.2
No cirrhosis 1060 66.0 (63.5 to 68.6) 997 73.6 (71.2 to 75.9) −63 7.5
  Non-cirrhotic, F3 154 9.6 (8.0 to 11.2) 137 10.1 (8.5 to 11.7) −17 0.5
  Non-cirrhotic, F0–F2 624 38.9 (36.3 to 41.5) 505 37.3 (34.7 to 39.8) −119 −1.6
  Non-cirrhotic, no 
score
282 17.6 (15.5 to 19.6) 355 26.2 (23.9 to 28.5) 73 8.6
  Missing information 93 5.8 (4.6 to 7.0) 54 4.0 (2.9 to 5.0) −39 −1.8
Child-Pugh score*
  A 323 71.5 (69.1 to 73.9) 199 65.5 (60.1 to 70.8) −124 −6.0
  B 55 12.2 (10.4 to 13.9) 43 14.1 (10.2 to 18.06) −12 2.0
  C 13 2.9 (2.0 to 3.8) 13 4.3 (0.0 to 6.6) 0 1.4
  Missing information 61 13.5 (11.7 to 15.3) 49 16.1 (12.0 to 20.3) −12 2.6
Continued
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the different centres. The number of patients enrolled 
with active HCV infection decreased between 2015 and 
2016 at Birmingham, Liverpool and Portsmouth, the 
more important decrease being observed at Birmingham 
(from 701 patients to 459 patients between 2015 and 
2016). Conversely, Hull experienced a substantial rise in 
the number of patients, increasing its enrolment by 94 
patients during the observation period (19.1% of total 
active HCV cohort in 2015 and 29.6% in 2016). These 
variations are likely to be related to the difference in 
the characteristics of the population covered by the 
different centres (online supplementary tables ST1a–
d); notably, about a third of patients with active HCV 
enrolled at Birmingham, Liverpool and Portsmouth in 
2015 had cirrhosis (32.4%, 33.2% and 38.4%, respec-
tively), compared with just 6.8% at Hull. Furthermore, 
the 2015 active HCV cohort at Birmingham, Liverpool 
and Portsmouth included few patients with current IVDU 
(2.1%, 10.3% and 7.1%, respectively); conversely, at Hull, 
this proportion was as high as 30.0%. Patients enrolled 
at Hull were also considerably younger than in the other 
three hospitals (41.6 years vs 48.3–53.2 years). Discrepan-
cies between centres are likely attributable to the target 
population, as Birmingham is a tertiary referral centre 
for complex/advanced liver disease including transplan-
tation, whereas Hull serves a large prison population.
Regarding the changes in the characteristics of the 
active HCV population across all four study centres 
(table 1 and online supplementary tables ST1a–d), no 
substantial differences between the two cohorts were 
observed in terms of age and genotype distribution. 
However, a 4.2% increase in the proportion of patients 
with current IVDU was observed, primarily attributable 
to the increased number of patients enrolled at Hull 
within the 2016 active HCV cohort. As mentioned above, 
IVDU was far more common among patients enrolled at 
this centre due to the volatility of the prison population, 
affecting 27.7% of patients in 2016 and 30.0% in 2015.
At the same time, a decrease in the proportion of 
patients with cirrhosis from 28.2% to 22.4% was observed, 
consistent with these patients being prioritised for 
treatment. The reduction in patients with cirrhosis was 
observed in patients enrolled at Birmingham, Liverpool 
and Portsmouth but not at Hull (online supplementary 
tables ST1a–d). Similarly, the proportion of transplanted 
patients (from 6.5% to 4.0%) and patients who are 
treatment-experienced (including both IFN-based and 
non-IFN-based regimens) also decreased (from 31.2% to 
27.1%) between 2015 and 2016. Generally, similar trends 
were observed between 2015 and 2016 active HCV cohorts 
when stratifying by GT1 and GT3 (online supplemen-
tary tables ST1e and ST1f, respectively). However, fewer 
post-transplant patients with active GT3 HCV infection 
were treated and removed from the cohort compared with 
GT1-infected patients, so that the number of post-trans-
plant patients with active GT1 HCV decreased from 48 in 
2015 to 15 in 2016 (online supplementary table ST1e), 
while the corresponding decrease for GT3 infection was 
from 49 to 33 patients (online supplementary table ST1f).
treatment patterns among patients remaining under follow-
up between 2015 and 2016
Among the 1451 patients from the 2015 active HCV 
cohort who remained in follow-up in 2016 (table 2), 154 
(10.6%) were on treatment or within 12 weeks of treat-
ment completion in 2015, while a further 424 (29%) 
patients commenced treatment during the study period. 
Treatment outcome was not yet known for 186 (12.8%) 
2015 active HCV cohort 2016 active HCV cohort
Changes in active HCV 
cohort between 2015 
and 2016
n % (95% CI) n % (95% CI)
Difference 
(n)
Difference 
(%)
Liver transplantation
  Transplanted 104 6.5 (5.2 to 7.8) 54 4.0 (2.9 to 5.0) −50 −2.5
  On transplantation 
list
6 0.4 (0.0 to 0.7) 6 0.4 (0.0 to 0.8) 0 0.1
  Missing 4 0.2 (0.0 to 0.5) 4 0.3 (0.0 to 0.6) 0 0.0
Prior treatment†
  Treatment-
experienced
502 31.3 (28.8 to 33.7) 367 27.1 (24.7 to 29.5) −135 −4.2
  Treatment-naive 1103 68.7 (66.3 to 71.2) 988 72.9 (70.5 to 75.3) −115 4.2
Continuous variables represented as mean. Categorical variables denoted as % (95% CI).
*Includes only patients with cirrhosis.
†Does not consider patients currently on treatment.
F0–F2, fibrosis stage 0–2; F3, fibrosis stage 3; GT1, genotype 1; GT2, genotype 2; GT3, genotype 3; HCV, hepatitis C virus; IVDU, intravenous 
drug use.
Table 1 Continued
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patients at the end of the study period, as they had not 
yet completed their treatment or were less than 12 weeks 
post-treatment. Overall across the four study centres, 
39.83% of patients from the 2015 active HCV cohort 
remaining in follow-up had been treated (with a known 
outcome) or were within 12 weeks post-treatment (treat-
ment outcome not yet known) during the 1-year observa-
tion period.
The proportion of treated patients varied substan-
tially according to cirrhosis status; 62.6% of patients with 
cirrhosis received HCV treatment during the study period, 
compared with only 31.6% of non-cirrhotic patients. 
IVDU status differed between treated and untreated 
patients; the proportion of the in-follow-up 2015 active 
HCV cohort who remained untreated between 2015 
and 2016 was higher in patients with current (89.8%) 
or prior (68.1%) IVDU than those who never injected 
drugs (45.0%). Regarding the cirrhosis status of patients 
with ongoing IVDU, in 2015 only 9.7% were cirrhotic 
and 75.8% were non-cirrhotic, with the remaining 14.5% 
non-specified due to omissions from patient notes. Thus, 
the trend for prioritising patients with cirrhosis for treat-
ment was reflected in the lower proportion of treated 
IVDU patients. Finally, treatment status differed by HCV 
genotype, so that the proportion of untreated patients 
was higher among patients with GT3 (64.4%) compared 
with GT1 (51.3%) HCV.
Surprisingly, 55.7% of patients with decompensated 
cirrhosis remained untreated during the study period. 
All 34 patients still had decompensated cirrhosis in 
2016: 1 of whom was on the transplant list, 13 (38.2%) 
were alive, 2 (5.9%) died from causes unrelated to 
HCV infection and 6 (17.6%) from HCV-related causes; 
the status of 3 (8.8%) patients was unknown, and 10 
(29.4%) patients had no new records during the subse-
quent follow-up, so that their outcomes could not be 
evaluated.
Regarding liver transplant status and treatment, 
more than half of 102 post-transplant patients (56.9%) 
received at least one HCV treatment during the study 
period.
Table 2 Treatment patterns and status in 2016
n
Treated or within 12 weeks of treatment completion between September 
2015 and September 2016
Untreated*All treated
On treatment or 
within 12 weeks 
of completion in 
September 2015†
Treated after 
September 2015 
and ≥12 weeks 
post-treatment by 
September 2016
Treated after 
September 2015 
and <12 weeks 
post-treatment 
by September 
2016
n (%) n (%) n (%) n (%) n (%)
All patients‡ 1451 578 (39.8) 154 (10.6) 238 (16.4) 186 (12.8) 873 (60.2)
IVDU
  Current IVDU 137 14 (10.2) 2 (1.5) 5 (3.7) 7 (5.1) 123 (89.8)
  Prior IVDU 626 200 (32.0) 53 (8.5) 80 (12.8) 67 (10.7) 426 (68.1)
  Never IVDU 280 154 (55.0) 39 (13.9) 68 (24.3) 47 (16.8) 126 (45.0)
Genotype
  GT1 642 313 (48.8) 88 (13.7) 111 (17.3) 114 (17.8) 329 (51.3)
  GT3 609 217 (35.6) 51 (8.4) 109 (17.9) 57 (9.4) 392 (64.4)
Liver disease status
  Any cirrhosis 428 268 (62.6) 83 (19.4) 135 (31.5) 50 (11.7) 160 (37.4)
  Compensated cirrhosis 361 237 (65.7) 71 (19.7) 124 (34.4) 42 (11.6) 124 (34.4)
  Decompensated cirrhosis 61 27 (44.3) 12 (19.7) 10 (16.4) 5 (8.2) 34 (55.74)
  Cirrhosis (no precision) 6 4 (66.7) 0 (0.0) 1 (16.7) 3 (50.0) 2 (33.3)
  No cirrhosis 942 298 (31.6) 68 (7.2) 97 (10.3) 133 (14.1) 644 (68.4)
  Non-cirrhotic, F3 145 54 (37.2) 7 (4.8) 30 (20.7) 17 (11.7) 91 (62.8)
  Non-cirrhotic, F0–F2 566 200 (35.3) 48 (8.5) 58 (10.3) 94 (16.6) 366 (64.7)
  Non-cirrhotic, no score 231 44 (19.1) 13 (5.6) 9 (3.9) 22 (9.5) 187 (81.0)
Liver-transplanted patients 102 58 (56.9) 37 (36.3) 14 (13.7) 7 (6.9) 44 (43.1)
Data are presented as n (%).
*Between September 2015 and September 2016.
†Did not receive any new treatment after September 2015.
‡All patients included in the 2015 active HCV cohort who had at least one visit since September 2014.
F0–F2, fibrosis stage 0–2; F3, fibrosis stage 3; GT1, genotype 1; GT3, genotype 3; IVDU, intravenous drug use.
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Outcomes in treated patients
Table 3 presents treatment received and its outcomes in 
the 383 patients from the 2015 active HCV cohort whose 
treatment outcome was known by 2016 (145 were already 
on treatment or within 12 weeks of completion in 2015, 
after the exclusion of 9 patients with no visits between 
2015 and 2016 and no available outcome data, and 238 
were newly treated during the observation period).
Treatment regimens received varied substantially 
according to genotype and cirrhosis status. All 22 treated 
patients with decompensated cirrhosis received an 
IFN-free regimen and 17 (77.3%) achieved SVR. One 
patient had no response to treatment, another inter-
rupted treatment due to adverse drug reaction, two 
(9.1%) patients relapsed, and one patient died of a cause 
unrelated to HCV infection.
Among the 191 treated patients with compensated 
cirrhosis, 98.9% of GT1 patients and 88.8% of GT3 
patients received an IFN-free regimen, while 10.1% of 
GT3 patients were treated with IFN±ribavirin (RBV)+so-
fosbuvir. Overall, 184 patients (96.3%) with compensated 
cirrhosis achieved SVR by 2016 (95.5% of GT1 and 96.6% 
of GT3), with 3 (1.6%) patients experiencing a relapse, 
2 (1.1%) dying from causes unrelated to HCV infection 
and two (1.1%) patients whose status was unknown.
A total of 160 non-cirrhotic patients were treated, of 
whom 56.3% and 33.6% were infected with GT1 and GT3 
HCV, respectively. Most (74.4%) GT1 patients received 
IFN-free regimens, compared with 51.9% of GT3 patients; 
20.0% of GT1 and 25.9% of GT3 patients were treated 
with IFN±RBV+DAA, while 3.3% of GT1 and 22.2% of GT3 
patients were treated with IFN±RBV. The vast majority of 
non-cirrhotic patients (91.9%) achieved SVR, including 
93.3% of GT1 and 88.9% of GT3 patients. One patient 
with GT1 disease had a viral breakthrough, one patient 
with GT1 and one with GT3 infection did not achieve a 
response, while two GT1 (2.2%) and one GT3 patients 
relapsed. Adverse drug reactions prompted discontinua-
tions of treatment in five non-cirrhotic patients (3.1%), 
of whom four (7.41%) had GT3 HCV. All four of these 
patients received IFN-based regimens (three were treated 
with IFN±RBV and one with IFN±RBV+DAA).
Patients lost to follow-up
Of the 1605 patients in the 2015 active HCV cohort, 154 
did not have a visit in the last 24 months prior to the 
2016 index date, and as such were considered LTFU. In 
comparison with those patients in the 2015 cohort who 
were not LTFU, patients who were subsequently LTFU 
were typically younger (44.9 vs 49.4 years) and more likely 
to be affected by current IVDU (18.2% vs 9.4%), non-cir-
rhotic (76.6% vs 64.9%) and treatment-naïve (76.6% vs 
67.9%) (table 4).
Table 3 Outcomes in treated patients
All patients
Patients with 
decompensated 
cirrhosis
Patients 
with compensated 
cirrhosis
Non-cirrhotic 
patients
n (%) n (%) n (%) n (%)
Treated between 2015 and 2016* 383 22 191 160
Most recent treatment
  IFN±RBV 20 (5.2) 0 (0.0) 2 (1.1) 18 (11.2)
  IFN±RBV+telaprevir/boceprevir 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.6)
  IFN±RBV+DAA 44 (11.5) 0 (0.0) 11 (5.8) 33 (20.6)
   DAA: simeprevir 15 (3.9) 0 (0.0) 2 (1.1) 13 (8.1)
   DAA: sofosbuvir 29 (7.6) 0 (0.0) 9 (4.7) 20 (12.5)
  IFN-free regimen 316 (82.5) 22 (100.0) 178 (93.2) 107 (66.9)
  Missing information 2 (0.5) 0 (0.0) 0 (0.0) 1 (0.6)
Outcome achieved by 2016
  Breakthrough 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.6)
  Dead (death not related to HCV infection) 3 (0.8) 1 (4.6) 2 (1.1) 0 (0.0)
  Interruption due to adverse drug reaction 6 (1.6) 1 (4.6) 0 (0.0) 5 (3.1)
  Non-response 3 (0.8) 1 (4.6) 0 (0.0) 2 (1.3)
  Relapse 8 (2.1) 2 (9.1) 3 (1.6) 3 (1.9)
  SVR achieved 357 (93.2) 17 (77.3) 184 (96.3) 147 (91.9)
  Unknown 5 (1.3) 0 (0.0) 2 (1.1) 2 (1.3)
Data presented as n (%).
*Includes patients treated prior to September 2015 whose treatment outcome was not yet known at the time (ie, they were <12 weeks from 
end of treatment).
DAA, direct-acting antiviral; HCV, hepatitis C virus; IFN, interferon; RBV, ribavirin; SVR, sustained virological response.
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Table 4 Difference in characteristics in 2015 between patients who were LTFU versus not LTFU in 2016
2015 not LTFU 2015 LTFU
n % (95% CI) n % (95% CI)
Overall population 1451 154
Centre
  Birmingham 664 45.8 (43.2 to 48.3) 37 24.0 (17.3 to 30.8)
  Hull 247 17.0 (15.1 to 19.0) 60 39.0 (31.3 to 46.7)
  Liverpool 431 29.7 (27.4 to 32.1) 54 35.1 (27.5 to 42.6)
  Portsmouth 109 7.5 (6.2 to 8.9) 3 1.9 (0.0 to 4.1)
Age at index date (years)
  Mean (SD) 49.36 (11.3) 44.88 (11.8)
  Median 49.0 43.5
  Q1–Q3 42–57 37–51
  Minimum–maximum 18–83 21–82
Male 1071 73.8 (71.5 to 76.1) 126 81.8 (75.7 to 87.9)
IVDU
  Current IVDU 137 9.4 (7.9 to 10.9) 28 18.2 (12.1 to 24.3)
  Prior IVDU 626 43.1 (40.6 to 45.7) 79 51.3 (43.4 to 59.2)
  Never IVDU 280 19.3 (17.3 to 21.3) 26 16.9 (11.0 to 22.8)
  Not recorded 408 28.1 (25.8 to 30.4) 21 13.6 (8.2 to 19.1)
Genotype
  GT1 642 44.2 (41.7 to 46.8) 62 40.3 (32.5 to 48.0)
  GT2 63 4.3 (3.3 to 5.4) 9 5.8 (2.1 to 9.5)
  GT3 609 42.0 (39.4 to 44.5) 51 33.1 (25.7 to 40.6)
  Other 103 7.1 (5.8 to 8.4) 17 11.0 (6.1 to 16.0)
  Missing information 34 2.3 (1.6 to 3.1) 15 9.7 (5.1 to 14.4)
Liver disease status
  Any cirrhosis 428 29.5 (27.2 to 31.8) 24 15.6 (9.9 to 21.3)
   Decompensated cirrhosis 61 4.2 (3.2 to 5.2) 6 3.9 (0.8 to 7.0)
   Compensated cirrhosis 361 24.9 (22.7 to 27.1) 17 11.0 (6.1 to 16.0)
   Cirrhosis (no precision) 6 0.4 (0.1 to 0.7) 1 0.6 (0.0 to 1.9)
  No cirrhosis 942 64.9 (62.5 to 67.4) 118 76.6 (69.9 to 83.3)
   Non-cirrhotic, F3 145 10.0 (8.4 to 11.5) 9 5.8 (2.1 to 9.5)
   Non-cirrhotic, F0–F2 566 39.0 (36.5 to 41.5) 58 37.7 (30.0 to 45.3)
   Non-cirrhotic, no score 231 15.9 (14.0 to 17.8) 51 33.1 (25.7 to 40.6)
  Missing information 81 5.6 (4.4 to 6.8) 12 7.8 (3.6 to 12.0)
Child-Pugh score*
  A 308 72.0 (67.7 to 76.2) 15 62.5 (43.1 to 81.9)
  B 50 11.7 (8.6 to 14.7) 5 20.8 (4.6 to 37.1)
  C 13 3.0 (1.4 to 4.7) 0 0.0 (0.0 to 0.0)
  Missing information 57 13.3 (10.1 to 16.5) 4 16.7 (1.8 to 31.6)
Liver transplantation
  Transplanted 102 7.0 (5.7 to 8.3) 2 1.3 (0.0 to 3.1)
  On transplantation list 6 0.4 (0.1 to 0.7) 0 0.0 (0.0 to 0.0)
  Missing 4 0.3 (0.0 to 0.5) 0 0.0 (0.0 to 0.0)
Prior treatment†
  Treatment-experienced 466 32.1 (29.7 to 34.5) 36 23.4 (16.7 to 30.1)
  Treatment-naive 985 67.9 (65.5 to 70.3) 118 76.6 (69.9 to 83.3)
Continuous variables represented as mean. Categorical variables denoted as % (95% CI).
*Includes only patients with cirrhosis.
†Does not consider patients currently on treatment.
F0–F2, fibrosis stage 0–2; F3, fibrosis stage 3; GT1, genotype 1; GT2, genotype 2; GT3, genotype 3; IVDU, intravenous drug use; LTFU, lost to follow-up.
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LTFU patients were differentially distributed between 
study centres. At Portsmouth and Birmingham, the rate 
of loss to follow-up did not exceed 6%. Conversely, high 
loss to follow-up rates were observed at Hull (60 of 307 
LTFU patients, 19.6%), attributable to the large prison 
population (explainable by greater levels of disengage-
ment and probability of moving regions on release), and 
Liverpool (54 of 485 LTFU patients, 11.1%). Hull was the 
largest contributor to the entire group of patients from 
the 2015 active HCV cohort who were LTFU, accounting 
for 60 of 154 (39.0%) patients, followed by Liverpool (54 
patients, 35.1%).
newly referred patients
Table 5 compares the baseline characteristics between 
the 337 patients who were newly referred to the study 
centres during the observation period and the 2015 active 
HCV cohort. Newly introduced patients, the majority of 
whom were enrolled at Hull, were on average younger 
than the 2015 active HCV cohort (45.1 vs 48.9 years) and 
more likely to be affected by current (18.7% vs 10.3%) or 
historical (51.9% vs 43.9%) IVDU. In terms of HCV geno-
type distribution, they were more often infected with GT1 
(48.7% vs 43.9%) and less frequently with GT3 (32.3% 
vs 41.1%) HCV. Newly referred patients were also more 
likely to be non-cirrhotic (76.9% vs 66.0%) than the 2015 
active HCV cohort, and very few were liver transplant 
recipients (0.6% vs 6.5% in the 2015 active HCV cohort).
DIsCussIOn
The introduction of DAAs has been described as a ‘step 
change’ in the management and outcomes of HCV,18 
representing the possibility of cure in most treated 
patients.5–7 Although early access programmes existed 
before June 2015, it was at about this time that DAAs were 
made available to patients with compensated cirrhosis 
treated in the National Health Service (NHS),15 although 
eligibility differed by genotype, extending to all GT1 
patients but only those GT3 patients who had contrain-
dications to IFN.15 From April 2016, access to DAAs was 
broadened to non-cirrhotic patients (but still prioritised 
to patients with cirrhosis). This staggered availability of 
DAA in different at-risk populations has meant that treat-
ment has been prioritised to patients with the most severe 
forms of HCV-related liver disease. This history of DAA 
access policies is important in interpreting the composi-
tion and outcomes of the HCV cohorts in this study. The 
two index dates in our study were chosen to describe how 
the characteristics of patients with HCV remaining in 
contact with specialised care evolved with this changing 
landscape of treatment and related health policy, to 
provide important real-world data on the outcomes of 
antiviral treatment among a diverse patient cohort, repre-
senting a number of genotypes and liver disease stages. 
Overall, SVR rate in treated patients was 93.2%, including 
91.9% in patients without liver cirrhosis and 96.3% in 
patients with compensated cirrhosis. However, despite 
all patients with decompensated cirrhosis receiving an 
IFN-free regimen (due to IFN being contraindicated in 
advanced liver disease), at 77.3%, SVR rate was consider-
ably lower among this difficult-to-treat patient group. The 
high SVR rates seen in our study are consistent with find-
ings from other studies conducted in a range of countries, 
which often evaluated substantial proportions of patients 
with cirrhosis, or those who have failed prior treatment 
and/or had significant comorbidities,8–11 suggesting that 
excellent real-world outcomes of DAA treatment are 
reproducible across a range of, often challenging, patient 
populations.
Viral genotype and liver disease stage critically influ-
enced the patient pathway. Treatment rate was more than 
double in patients with compensated cirrhosis compared 
with non-cirrhotic patients, although a progressive 
increase in the number of treated non-cirrhotic patients 
was observed over the study period. Furthermore, patients 
who were newly referred to the study centres during the 
observation period were more likely to be non-cirrhotic 
than patients from the prevalent 2015 active HCV cohort. 
These differences reflect the evolution of the recommen-
dations regarding the use of the new DAAs during the 
study period, in England, with initial restriction of the use 
of DAAs for patients with severe liver damage. Of note, 
further treatments, including those for GT3-infected 
patients, became available on the NHS after the study 
period, so that therapy may have been deferred until their 
availability for some GT3 patients who would have received 
IFN during the period of our study. Treatment options 
availability could, therefore, explain the fewer GT3 than 
GT1 patients treated during the study period, and SVR 
was somewhat lower in patients infected with GT3 than 
GT1, most likely reflecting lower usage of IFN-free treat-
ment in GT3 patients. Substantially more post-transplant 
patients with a GT1 infection were treated and removed 
from the active HCV cohort by 2016 compared with 
GT3-infected patients. Despite post-transplant patients 
being prioritised for treatment, due to their susceptibility 
to aggressive HCV progression in the setting of immuno-
suppression, only IFN-containing regimens were available 
to most GT3 patients at the time of our study. Also, the 
cohort of patients who were newly referred during the 
observation period included fewer GT3 patients than the 
prevalent 2015 active HCV cohort. Our results therefore 
suggest that a watch-and-wait approach was preferred in 
some GT3 patients pending the commissioning of an 
IFN-free regimen.
We have characterised patients who were LTFU during 
the observation period (ie, had no visits in the 24-month 
period prior to 2016), as these patients may be particu-
larly difficult to engage and retain in care. It is, however, 
worth noting some LTFU patients may have moved, rather 
than disengaged with specialist care altogether, as we 
were unable to distinguish between these two situations. 
Patients who were LTFU were younger, more frequently 
male, more likely to be affected by current IVDU, have 
no cirrhosis and no prior treatment experience; the latter 
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Table 5 Difference in characteristics between the 2015 active cohort and those newly introduced in 2016
2015 active HCV cohort 2016 newly introduced
n % (95% CI) n % (95% CI)
Overall population 1605 337
Centre
  Birmingham 701 43.7 (41.2 to 46.1) 36 10.7 (7.4 to 14.0)
  Hull 307 19.1 (17.2 to 21.1) 201 59.6 (54.4 to 64.9)
  Liverpool 485 30.2 (28.0 to 32.5) 82 24.3 (19.8 to 28.9)
  Portsmouth 112 7.0 (5.7 to 8.2) 18 5.3 (2.9 to 7.7)
Age at index date (years)
  Mean (SD) 48.9 (±11.4) 45.1 (±10.7)
  Median 49 44
  Q1–Q3 41–56 38–52
  Minimum–maximum 18–83 21–80
Male 1197 74.6 (72.4 to 76.7) 245 72.7 (67.9 to 77.5)
IVDU
  Current IVDU 165 10.3 (8.8 to 11.8) 63 18.7 (14.5 to 22.9)
  Prior IVDU 705 43.9 (41.5 to 46.4) 175 51.9 (46.6 to 57.3)
  Never IVDU 306 19.1 (17.1 to 21.0) 68 20.2 (15.9 to 24.5)
  Not recorded 429 26.7 (24.6 to 28.9) 31 9.2 (6.1 to 12.3)
Genotype
  GT1 704 43.9 (41.4 to 46.3) 164 48.7 (43.3 to 54.0)
  GT2 72 4.5 (3.5 to 5.5) 21 6.2 (3.7 to 8.8)
  GT3 660 41.1 (38.7 to 43.5) 109 32.3 (27.3 to 37.3)
  Other 106 6.6 (5.4 to 7.8) 24 7.1 (4.4 to 9.9)
  Missing information 63 3.9 (3.0 to 4.9) 19 5.6 (3.2 to 8.1)
Liver disease status
  Any cirrhosis 452 28.2 (23.4 to 33.0) 66 19.6 (15.3 to 23.8)
   Decompensated cirrhosis 67 4.2 (3.2 to 5.2) 18 5.3 (2.9 to 7.7)
   Compensated cirrhosis 378 23.6 (21.5 to 25.6) 47 13.9 (10.2 to 17.6)
   Cirrhosis (no precision) 7 0.4 (0.0 to 0.8) 1 0.3 (0.0 to 0.9)
  No cirrhosis 1060 66.0 (63.7 to 68.4) 259 76.9 (72.4 to 81.4)
   Non-cirrhotic, F3 154 9.6 (8.2 to 11.0) 50 14.8 (11.0 to 18.6)
   Non-cirrhotic, F0–F2 624 38.9 (36.5 to 41.3) 101 30.0 (25.1 to 34.9)
   Non-cirrhotic, no score 282 17.6 (15.7 to 19.4) 108 32.0 (27.1 to 37.0)
  Missing information 93 5.8 (4.7 to 6.9) 12 3.6 (1.6 to 5.5)
Child-Pugh score*
  A 323 71.5 (67.3 to 75.6) 33 50.0 (37.9 to 62.1)
  B 55 12.2 (9.2 to 15.2) 12 18.2 (8.9 to 27.5)
  C 13 2.9 (0.0 to 4.4) 9 13.6 (0.0 to 21.9)
  Missing information 61 13.5 (10.3 to 16.6) 11 16.7 (7.7 to 25.7)
Liver transplantation
  Transplanted 104 6.5 (5.3 to 7.7) 2 0.6 (−0.2 to 1.4)
  On transplantation list 6 0.4 (0.0 to 0.7) 5 1.5 (0.0 to 2.8)
  Missing 4 0.2 (0.0 to 0.5) 1 0.3 (−0.3 to 0.9)
Prior treatment†
  Treatment-experienced 502 31.3 (29.0 to 33.5) 77 22.8 (18.4 to 27.3)
  Treatment-naive 1103 68.7 (66.5 to 71.0) 260 77.2 (72.7 to 81.6)
Continuous variables represented as mean. Categorical variables denoted as % (95% CI).
*Includes only patients with cirrhosis.
†Does not consider patients currently on treatment.
F0–F2, fibrosis stage 0–2; F3, fibrosis stage 3; GT1, genotype 1; GT2, genotype 2; GT3, genotype 3; HCV, hepatitis C virus; IVDU, intravenous drug use.
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may reflect a more recent HCV diagnosis or a lack of 
commitment to long-term treatment. Nonetheless, about 
one in six LTFU patients had cirrhosis, with the associ-
ated risk of progression to decompensated cirrhosis and 
a 5%–30% 5-year risk of developing liver cancer.2 Patients 
with current IVDU were not prioritised for treatment 
during the study period and 89.8% of them remained 
untreated, compared with just 45.0% of those with no 
IVDU history, so there was no specific incentive for IVDU 
patients to remain in care. Thus, keeping younger, male 
IVDU patients engaged with care appears a challenge, 
exemplified further by the substantial patient turnover at 
Hull, a centre serving a large prison population, where 
patients were more commonly younger and intravenous 
drug users than at the remaining centres. Nearly one 
in five patients from the active 2015 cohort enrolled at 
Hull were LTFU by 2016, while, conversely, the centre 
accounted for 59.6% of new referrals over the 1-year 
observation period. The likely explanation for this high 
turnover rate is that incarcerated patients with HCV are 
engaged with healthcare services, but do not continue 
with care at the Hull centre once released either because 
of disengagement or because of relocation to another 
geographical location following release. Future initiatives 
promoting engagement and treatment of young, male, 
IVDU patients, as well as patients released from prison 
appear of particular value to both individual patients 
and public health, as ongoing IVDU in the presence of 
an active HCV infection presents a high risk of disease 
spread, which may be reduced by effective treatment. 
Re-engaging these patients with healthcare services is a 
high priority, especially since LTFU patients before DAA 
treatment was widely available may not be aware of their 
present eligibility for IFN-free therapy.
While providing valuable information, our study has 
several limitations. First, we only included patients and 
collected information from selected centres. Thus, the 
generalisability of our findings should be considered 
against the study setting and the range of data collected; 
for instance, we may have been unable to fully capture the 
characteristics of patients difficult to engage with health-
care services, as some would not have been included in 
our study due to lack of contact with the study centres. 
Another limitation of our study relates to its relatively 
short (12 months) observation period, which did not 
fully span the evolution of HCV treatment in the UK 
from IFN-based to fully DAA-based. Consequently, the 
dynamic developments in the treatment of HCV in the 
last 2 years may mean that the characteristics of patients 
currently receiving treatment have changed from those 
described in our study. Finally, the retrospective nature 
of data collection could subject it to issues related to data 
access, completeness and accuracy, for example data 
entry errors.
Overall, our study demonstrated high cure rates 
achieved in UK patients with HCV as access to DAAs was 
progressively broadened during the observation period. 
However, there remains an unmet need for uniform 
access to DAAs among treatment-naïve patients with 
early stages of liver disease, and among disadvantaged 
and marginalised populations. Broadening DAA access 
and facilitating adherence to treatment may ultimately 
achieve HCV elimination and, consequently, removing 
the substantial burden that this disease poses on patients 
and healthcare services.
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